Free Analog SFF, September 2010 by Dell Magazine Authors

dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348(9019):7-12.
    3 Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, et al. “Mortality in the Survival With Oral D-sotalol (SWORD) trial: why did patients die?” Am J Cardiol 1998;81(7):869-76.
    4 Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. “Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.” N Engl J Med 1991;324(12):781-8.
    5 Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW. The Cardiac Arrhythmia Suppression Trial: first CAST . . . then CAST-II. J Am Coll Cardiol 1992;19(5):894-8.
    6 “Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.” The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992;327(4):227-33.
    7 Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350(9089):1417-24.
    8 Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 “Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.” Circulation 2008;117(21):2820-40.
    9 Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. “Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial.” Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55.
    10 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.” N Engl J Med 2000;343(21):1520-8.
    11 Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. “Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.” Circulation 2007;115(12):1634-42.
    12 Sachdev M, Miller WC, Ryan T, Jollis JG. “Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.” Am Heart J 2002;144(6):1065-73.
    13 Fishman AP. “Aminorex to fen/phen: an epidemic foretold.” Circulation 1999;99(1):156-61.
    14 Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. “Estrogen plus progestin and the risk of coronary heart disease.” N Engl J Med 2003;349(6):523-34.
    15 Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. “Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.” Circulation 2006;113(20):2425-34.
    16 Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. “Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.” Circulation 2007;115(11):1481-501.
    17 Silverman WA. “The schizophrenic career of a “monster drug.” Pediatrics 2002;110(2 Pt 1):404-6.
    18 Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361(20):1963-71.
    19 McLaughlin JK, Lipworth L, Murphy DK, Walker PS. “The safety of silicone gel-filled breast implants: a review of the epidemiologic evidence.” Ann Plast Surg 2007;59(5):569-80.
    20 Lenzer J. “The Super Cell.” Discover 2009(September):30-36.
    21 Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. “Cardiac cell repair therapy: a clinical perspective.” Mayo Clin Proc 2009;84(10):876-92.
    22 Lerner EM. “Follow the Nanobrick Road.” Analog Science Fiction and